EARNINGS: Pfizer slumped as its first-quarter sales fell short of estimates. The maker of pain medicine Lyrica and the blockbuster Prevnar 13 vaccine against pneumococcal infections said sales of older medicines slipped and its stock lost 2.3 percent. Merck fell 1.1 percent to $58.23 following its report. AbbVie gained 6.1 percent to $102.49 after it said it will buy back $7.5 billion of its own stock.
Coming off that $39, looks like a nice swing trade Pfizer Lifts 2019 Earnings Forecast as Biopharma Sales Drive Q1 Profit Beat Pfizer posted stronger-than-expected first quarter earnings Tuesday, and boosted the mid-point of its full-year profit forecast thanks to anticipated gains in consumer healthcare.
Cheaper generics for sure, continued declining sales. But this is not going to be some sort of surprise, the market has known about this and has discounted it already. https://www.statista.com/statistics/264827/pfizers-worldwide-viagra-revenue-since-2003/ Pfizer’s worldwide known erectile dysfunction product Viagra generated around 640 million U.S. dollars in revenue in 2018. Sales of this drug have decreased steadily over the past seven years, especially because patent protection expired outside the U.S. in 2012. In the United States, several drug manufacturers are currently allowed to market generic versions of Viagra (sildenafil), even if the patent is set to expire in 2020. This was the reason behind a further significant decline in sales in 2017-2018
Dividend Stock Spotlight: Pfizer (PFE) Mon, Sep 30, 2019 Health Care has had a lack-luster year with the worst YTD performance of the 11 sectors. Pfizer (PFE) has been a prime example of this. The stock had been in a long term uptrend over the past several years, and after a big move higher in early 2018, 2019 has been another story. After a few lower lows over the past year, the stock fell dramatically in August in response to disappointing earnings. Although the damage has been done in regards to the near term technical picture, the longer-term uptrend is still in place. Additionally, from a dividend-focused point of view, it is one of the best in the Health Care sector. This recent drop sent the yield much higher. At just a hair under 4%, PFE currently has the third-highest dividend yield of all S&P 500 Health Care stocks. Additionally, the company has raised that dividend consistently over the past decade. Even with that high yield, the dividend payout ratio is only at 39% meaning the company has the earnings to cover or even raise its payout. In a post in late August, we highlighted PFE's massive decline in response to its last earnings report which led the dividend yield to spike higher. In turn, the yield drastically distanced itself from the yield on another major Dow Health Care stock, Merck (MRK). Since then, given the price has yet to move back to where it previously was, PFE's yield continues to be much higher than that of MRK. Though it is off its recent high, the difference between the two stocks' yields is right near the highest levels of the current cycle.
7/22/2020 Nearly 36,000 Robinhood users added Pfizer shares Wednesday after the US government ordered 100 million doses of its coronavirus vaccine (PFE) https://markets.businessinsider.com...-vaccine-deal-gained-bought-2020-7-1029421968
Market cap is nuts on this lots of room to move after this downtrend is broke. On a nice support at 38 from few years ago. Picked up 50 shares. Hold for a month will go up from here:
